{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:53:00Z","timestamp":1792111980608,"version":"4.4.0"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Based on extrapolation of similar clinical outcomes in rheumatoid arthritis to the originator infliximab (IFX) in randomized clinical trials, the first biosimilar antibody CT\u2010P13 was approved for the treatment of psoriasis. To evaluate the safety, efficacy, and drug survival of CT\u2010P13 for psoriasis in real\u2010world clinical practice, prospective post\u2010marketing surveillance was conducted in 165 Japanese psoriasis patients. During a 1\u2010year follow\u2010up period, adverse drug reactions (ADRs) occurred in 29 patients (17.6%). Infusion reaction was the most frequent ADR (6.7%), and mild pneumonia was reported as the only case of infection. Serious ADRs were reported in two patients (1.2%): acute cholecystitis and interstitial pneumonia. The interstitial pneumonia developed after a single infusion of CT\u2010P13 and the patient died of respiratory failure. In naive patients to biologic therapy (<jats:italic>n<\/jats:italic>\u00a0=\u200944), the Psoriasis Area Severity Index (PASI) decreased rapidly after the start of CT\u2010P13 treatment, and response rate achieving an absolute PASI score &lt;1 was 55% at 30\u2009weeks. The response rate was high (78%) in patients with psoriatic arthritis, and 40% and 20% in those in plaque psoriasis and pustular psoriasis, respectively. Of patients switched from IFX to CT\u2010P13 mainly for nonmedical reasons (<jats:italic>n<\/jats:italic>\u00a0=\u2009105), 57% had already reached PASI &lt;1 by pretreatment with IFX and CT\u2010P13 maintained this status. The incidence of ADRs in this patient group was low and the drug survival rate was as high as 74%, even at 1\u00a0year, which was significantly higher than that in the na\u00efve patient group (47%). Patients switched from other biologics for medical reasons (<jats:italic>n<\/jats:italic>\u00a0=\u200916) responded similarly to biologic\u2010na\u00efve patients, but drug survival was lower (24%). In conclusion, CT\u2010P13 showed excellent effectiveness as a first\u2010line therapy, no clinical difficulties in switching from IFX, and usefulness in patients who failed other biologics. CT\u2010P13 could be a cost\u2010effective alternative to IFX for the treatment of psoriasis.<\/jats:p>","DOI":"10.1111\/1346-8138.16508","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T01:17:29Z","timestamp":1657243049000},"page":"957-969","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety, efficacy, and drug survival of the infliximab biosimilar <scp>CT\u2010P13<\/scp> in post\u2010marketing surveillance of Japanese patients with psoriasis"],"prefix":"10.1111","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"first","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2350-6189","authenticated-orcid":false,"given":"Kiyohiro","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Quality and Pharmacovigilance Division Pharmaceuticals Group, Nippon Kayaku Co., Ltd.  Tokyo Japan"},{"name":"Asajes Ventures  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumika","family":"Yamada","sequence":"additional","affiliation":[{"name":"Quality and Pharmacovigilance Division Pharmaceuticals Group, Nippon Kayaku Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mie University Graduate School of Medicine  Tsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kochi Medical School, Kochi University  Nankoku Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Jichi Medical University  Shimotsuke Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"e_1_2_7_2_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"4","author":"Sbidian E","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203091"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203090"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1022297"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2016.1206244"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32196-2"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01834-3"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666161014153346"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15659"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00507-1"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2019.00030"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15399"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roab068"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13214"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12239"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18333"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.01.022"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.001"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06502.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000527"},{"key":"e_1_2_7_25_1","unstructured":"World Health Organization.Global Tuberculosis Report 2021. (issued14 October 2021). Accessed 8 May 2022.https:\/\/www.who.int\/teams\/global\u2010tuberculosis\u2010programme\/tb\u2010reports\/global\u2010tuberculosis\u2010report\u20102021"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00475-8"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34293-y"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15146"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16205"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40324"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12364"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000156599"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17738"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.16508","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:48:10Z","timestamp":1758721690000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/1346-8138.16508"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16508","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"2022-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}